Valproate Administered after Traumatic Brain Injury Provides Neuroprotection and Improves Cognitive Function in Rats
Authors:
Open Access
- 30 June 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (6) , e11383
Abstract
Traumatic brain injury (TBI) initiates a complex series of neurochemical and signaling changes that lead to pathological events including neuronal hyperactivity, excessive glutamate release, inflammation, increased blood-brain barrier (BBB) permeability and cerebral edema, altered gene expression, and neuronal dysfunction. It is believed that a drug combination, or a single drug acting on multiple targets, may be an effective strategy to treat TBI. Valproate, a widely used antiepileptic drug, has a number of targets including GABA transaminase, voltage-gated sodium channels, glycogen synthase kinase (GSK)-3, and histone deacetylases (HDACs), and therefore may attenuate a number of TBI-associated pathologies. Using a rodent model of TBI, we tested if post-injury administration of valproate can decrease BBB permeability, reduce neural damage and improve cognitive outcome. Dose-response studies revealed that systemic administration of 400 mg/kg (i.p.), but not 15, 30, 60 or 100 mg/kg, increases histone H3 and H4 acetylation, and reduces GSK-3 activity, in the hippocampus. Thirty min post-injury administration of 400 mg/kg valproate improved BBB integrity as indicated by a reduction in Evans Blue dye extravasation. Consistent with its dose response to inhibit GSK-3 and HDACs, valproate at 400 mg/kg, but not 100 mg/kg, reduced TBI-associated hippocampal dendritic damage, lessened cortical contusion volume, and improved motor function and spatial memory. These behavioral improvements were not observed when SAHA (suberoylanilide hydroxamic acid), a selective HDAC inhibitor, was administered. Our findings indicate that valproate given soon after TBI can be neuroprotective. As clinically proven interventions that can be used to minimize the damage following TBI are not currently available, the findings from this report support the further testing of valproate as an acute therapeutic strategy.Keywords
This publication has 72 references indexed in Scilit:
- Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injuryThe FASEB Journal, 2009
- Cocaine-induced hyperactivity and sensitization are dependent on GSK3Neuropharmacology, 2009
- Traumatic brain injury-induced expression and phosphorylation of pyruvate dehydrogenase: A mechanism of dysregulated glucose metabolismNeuroscience Letters, 2009
- Food restriction induces long-lasting recovery of spatial memory deficits following global ischemia in delayed matching and non-matching-to-sample radial arm maze tasksNeuroscience, 2008
- HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in ratsBrain Research, 2008
- Neurotrophin-mediated neuroprotection of hippocampal neurons following traumatic brain injury is not associated with acute recovery of hippocampal functionNeuroscience, 2007
- Immunohistological markers for staging neurogenesis in adult hippocampusCell and tissue research, 2007
- Dynamics of neurogenesis in the dentate gyrus of adult ratsNeuroscience Letters, 2005
- Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neuronsThe Pharmacogenomics Journal, 2004
- Bodyweight Gain and AnticonvulsantsDrug Safety, 2001